Patients with three or more primary melanomas: clinical-epidemiological study

. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62:177--88. . Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol. 2011;65:949--56. . Conic RRZ, Chu S, Tamashunas NL, Damiani G, Bergfeld W. Prevalence of cardiac and metabolic diseases among patients with alopecia areata. J Eur Acad Dermatology Venereol. 2021;35:e128--9. . Lee S, Lee YB, Kim BJ, Lee WS. Screening of thyroid function and autoantibodies in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80, 141013.e4. . Park SM, Oh YJ, Lew BL, Sim WY. The association among thyroid dysfunction, thyroid autoimmunity, and clinical features of 8. Porter D, Burton JL. Comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol. 1971;85:272--3. 9. Pirmez R, Abraham LS, Duque-Estrada B, Damasco P, Farias DC, Kelly Y, et al. Trichoscopy of steroid-induced atrophy. Skin Appendage Disord. 2017;3:171--4.

Patients with three or more primary melanomas: clinical-epidemiological study ଝ

Dear Editor,
The incidence of malignant melanoma is growing worldwide and melanoma is responsible for most skin cancer-related deaths. 1 Patients with melanoma undergo follow-up visits mainly to avoid disease progression. 2 Moreover, the diagnosis of melanoma has been reported to be a risk factor for subsequent melanoma development. 3 The majority of patients with multiple primary melanomas (MPM) have two primary tumors and only a small part of them has three or more primary melanomas (3PM). The literature is almost exclusively focused on the group of MPM patients as a whole and does not address patients with more than two primary tumors. 4 We used a database of patients who followed up with malignant melanoma at the university department (Department of Dermatovenereology, University Hospital, Pilsen, Czech Republic) to find a cohort of patients with MPM. We focused on patients with 3PM to analyze them in detail in the range of retrospective studies.
We were interested in the gender, age at first melanoma excision, the total number of removed primary melanomas, the time interval between surgical excisions of MPMs, histopathological classification of all melanomas (AJCC classification at the time of tumor excision), location of all melanomas (head/neck, torso, upper limbs, lower limbs, other), development of nodal and/or distant metastases during follow-up. We also searched for melanoma in the family (to the second line of close relatives), coincidence with another type of cancer, phototype (I---IV according to Fitzpatrick's classification), three or more episodes of sunburn in childhood (yes/no/I don't know), and the number and character of melanocytic nevi on the trunk and proximal parts of extremities (group 0 ---no nevi, I ---up to 20 nevi, II ---up to 50 nevi, III ---more than 50 common nevi, IV --more than 50 nevi of different clinical appearance, including atypical nevi).
We identified 3641 patients who followed up for histopathologically confirmed malignant melanoma in the electronic database of our department, for whom all required information was available. We found 201 patients with MPM among them, which represents 5.52% of the cohort. Two primary melanomas were excised in 161 patients, and three or more primary melanomas (3PM) in the remaining 40 patients (1.10% of the whole cohort and 19.90% of the MPM group).
The 3PM group (40 patients) consists of 24 patients with three primary melanomas, 8 patients with four primary tumors, 4 patients with five primary tumors, 1 patient with six primary tumors, and 3 patients with seven primary melanomas (Figs. 1---3).
The group consists of 26 men (65.00%) and 14 women (35.00%) with a mean age of 57.48 years (range 24---77 years) at the time of the first melanoma excision. The family history is positive for melanoma in 12 patients (30.00%). All phototypes I---IV are represented and 35 patients (87.50%) were repeatedly sunburned in childhood. Patients with 3PM tend to have a high number of melanocytic nevi; 21 patients  We usually removed thinner subsequent primary melanomas in 3PM patients (1 st melanoma ---22.50% in situ, 40.00% stage I, 37.50% stage II; 2 nd melanoma ---57.50% in situ, 37.50% stage I, 5.00% stage II; 3 rd melanoma ---70.00% in situ, 27.50% stage I, 2.50% stage II). We excised only multiple in situ melanomas in 5 patients (three tumors in 3 patients and four tumors in 2 patients). Nineteen patients (47.50%) had excised only in situ or stage IA melanomas.
The first melanoma was most often located on the trunk (19 patients, 47.50%) and all primary melanomas occurred in the same location in 9 cases (22.50%).   The first and second melanomas in the same patient were frequently removed synchronously (0---2 months interval; 10 patients, 25.00%) or within 2---12 months (9 patients, 22.50%). On the contrary, the second melanoma occurred in more than 5 years in 14 patients (35.00%). The third melanoma was removed synchronously with the first tumor in 2 patients (5.00%), within 12 months, within 1---5 years, and within 5---10 years equally in 9 patients (22.50%) and in more than 10 years after the first tumor in the remaining 11 patients (27.50%). In 3 patients with seven primary melanomas, all seven tumors were removed within 11, 14, and 20 years, respectively. The youngest patient had a third primary melanoma excised at 35 years of age; in most patients (31 patients, 77.50%) this occurred after 60 years of age.
Nodal and/or distant metastases of melanoma occurred in 8 patients (20.00%) at 3PM. We found the coincidence of melanoma with another type of cancer in 14 patients (35.00%).
The internal morbidity of patients with 3PM did not significantly exceed the morbidity of the general population; mainly represented by arterial hypertension (52.50%), cardiac disease (30.00%), gall bladder/liver disease (17.50%), diabetes (15.00%), lipid metabolism disorders (15.00%), thyroid gland disease (10.00%). Table 1 offers characteristics of 3PM group, as well as its comparison with the MPM group and single primary melanoma group ---SPM (control group of 1591 patients with SPM removed between January 2010 and December 2019). Both MPM and 3PM groups are more often represented by men, younger patients, lighter phototypes, patients with multiple and atypical melanocytic nevi, people with a history of sunburn, and a history of melanoma in the family compared to the SPM group. Moreover, patients with 3PM are more at risk of developing nodal and/or distant metastases of melanoma as well as another type of cancer. Differences in family history positivity, number and character of melanocytic nevi, and coincidence with skin cancer were found to be statistically highly significant when comparing 3PM vs. SPM, but also 3PM vs. MPM patients.
In conclusion, we can state that MPM patients have more expressed well-known risk factors for malignant melanoma, which is even more pronounced in 3PM patients. 5,6 According to our results, 3PM patients also have an increased risk of melanoma metastases and coincidence with another type of cancer. 7,8 Long-term follow-up of patients with melanoma, as well as patients with melanoma risk factors, is important. 9,10 The genetic testing of MPM patients and their tumors would be interesting and could be the subject of further research.

Financial support
None declared.

Author's contributions
Tomas Fikrle: Approval of the final version of the manuscript; critical literature review; data collection, analysis and interpretation; effective participation in research orientation; intellectual participation in propaedeutic and/or therapeutic; management of studied cases; preparation and writing of the manuscript; statistical analysis; study conception and planning.
Barbora Divisova: Critical literature review; data collection, analysis, and interpretation; intellectual participation in propaedeutic and/or therapeutic; management of studied cases.
Karel Pizinger: Approval of the final version of the manuscript; effective participation in research orientation; manuscript critical review.

Conflicts of interest
None declared.